Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
EBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsShares IssuedShares OutstandingWages, Salaries and Other
Ratios

Ptc Therapeutics (PTCT) Accumulated Depreciation & Amortization (2016 - 2024)

Historic Accumulated Depreciation & Amortization for Ptc Therapeutics (PTCT) over the last 13 years, with Q4 2024 value amounting to $33.4 million.

  • Ptc Therapeutics' Accumulated Depreciation & Amortization fell 3494.17% to $33.4 million in Q4 2024 from the same period last year, while for Dec 2024 it was $33.4 million, marking a year-over-year decrease of 3494.17%. This contributed to the annual value of $33.4 million for FY2024, which is 3494.17% down from last year.
  • Ptc Therapeutics' Accumulated Depreciation & Amortization amounted to $33.4 million in Q4 2024, which was down 3494.17% from $51.3 million recorded in Q4 2023.
  • Over the past 5 years, Ptc Therapeutics' Accumulated Depreciation & Amortization peaked at $51.3 million during Q4 2023, and registered a low of $18.1 million during Q4 2020.
  • Over the past 5 years, Ptc Therapeutics' median Accumulated Depreciation & Amortization value was $33.4 million (recorded in 2024), while the average stood at $33.4 million.
  • Its Accumulated Depreciation & Amortization has fluctuated over the past 5 years, first plummeted by 4387.2% in 2020, then skyrocketed by 5044.29% in 2021.
  • Ptc Therapeutics' Accumulated Depreciation & Amortization (Quarter) stood at $18.1 million in 2020, then surged by 50.44% to $27.2 million in 2021, then skyrocketed by 37.52% to $37.4 million in 2022, then skyrocketed by 37.21% to $51.3 million in 2023, then plummeted by 34.94% to $33.4 million in 2024.
  • Its Accumulated Depreciation & Amortization stands at $33.4 million for Q4 2024, versus $51.3 million for Q4 2023 and $37.4 million for Q4 2022.